Krsnaa Diagnostics to raise ₹91.75 crore via preferential issue of warrants
Krsnaa Diagnostics plans to raise ₹91.75 crore via preferential issue of 16,21,000 warrants. The issue price is ₹566 per warrant. Investors include Mr. Rajendra Mutha and Krsnaa Diagnostics (Mumbai) Private Limited. Warrants are convertible within 18 months of allotment.
The fundraising amount of approximately ₹91.75 crore is material for the company's size and could impact its financial structure and operational capacity. The preferential issue to specific investors also suggests strategic alignment.
The announcement details a significant fundraising initiative through a preferential issue, which is generally viewed positively as it can strengthen the company's financial position and fund growth opportunities.
Krsnaa Diagnostics Limited announced its plan to raise approximately ₹91.75 crore through a preferential issue of warrants on a private placement basis. The company will issue up to 16,21,000 warrants, each convertible into one fully paid-up equity share of face value ₹5.
The issuance is being made under Section 62(1)(c) read with Section 42 of the Companies Act, 2013, and Chapter V of the SEBI (ICDR) Regulations, 2018. The issue price for the warrants is ₹566 per warrant, determined as of August 18, 2026.
The warrants will be issued to two investors: Mr. Rajendra Mutha, who will receive 75,000 warrants for ₹4.25 crore, and Krsnaa Diagnostics (Mumbai) Private Limited, which will receive 15,46,000 warrants for ₹87.50 crore. Post-allotment, Mr. Rajendra Mutha's shareholding is expected to be 23.79%, and Krsnaa Diagnostics (Mumbai) Private Limited's shareholding will increase to 6.78% from the pre-issue 2.36%.
Each warrant can be exercised in one or more tranches within 18 months from the date of allotment. The company has submitted this information to BSE Limited and the National Stock Exchange of India Limited.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.